Daniel Irizarry, MD, a former physician and patient living with PD, discussed how hands-on simulation training could enhance clinician empathy and improve treatment strategies.

Continuous subcutaneous apomorphine infusion enhances confidence and reduces treatment burden for Parkinson's patients, improving daily activity engagement.

Cynthia Fox, PhD, CCC-SLP, CEO and co-founder of LSVT Global, discussed the evolution of rehabilitative therapies in PD and stressed early referrals for speech, physical, and occupational therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 27, 2025.

UCB has recently announced promising phase 3 trial results of fenfluramine, a potential new treatment to enhance seizure control for CDKL5 deficiency disorder.

The design of a phase 2 study, presented at ATMRD 2025, highlighted the trial’s patient-focused approach, allowing patients with Parkinson disease to complete visits either at home or in a clinic.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joseph Sullivan, MD. [LISTEN TIME: 14 minutes]

A recent survey reveals critical gaps in neurology training on women's health, highlighting the need for urgent curriculum reforms in medical education.

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the clinical utility, supporting data, and practical use cases for STS101, a newly approved nasal powder formulation of dihydroergotamine for acute migraine.

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

Skyhawk Therapeutics initiates FALCON-HD trial for SKY-0515, a promising treatment for Huntington disease, aiming to modify disease progression.

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Jennifer Robblee, MD, MSc, headache neurologist at the Barrow Neurological Institute, talked about an expert panel that developed a consensus definition for refractory migraine.

Veronica Hood, PhD, chief scientific officer at the Dravet Syndrome Foundation, discussed the evolving care landscape of Dravet syndrome, highlighting breakthroughs in precision medicine and promising new therapies for patients.

Nathaniel M. Schuster, MD, associate clinic director at the UC San Diego, talked about findings from a study of vaporized cannabis in treating patients with acute migraine presented at AHS 2025.

Here's some of what is coming soon to NeurologyLive® this week.

Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pediatric neurology.

Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 20, 2025.